The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines

Xuan Lin , Hongguang Xiang , Jiong Wu , Ruixi Liao , Yuhao Li , Bohui Xu , Ying Xu , Yan Shen , Qian Li , Yu Tian

Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101121

PDF (6591KB)
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) :101121 DOI: 10.1016/j.ajps.2026.101121
Review Article
research-article
The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines
Author information +
History +
PDF (6591KB)

Abstract

Nucleic acid-based therapies have emerged as promising strategies for the regulation of gene expression and the production of therapeutic antigens or proteins for a series of diseases, including cancers, rare diseases, and infectious diseases. However, their clinical application faces challenges. These include high molecular weight, limited cellular uptake, and susceptibility to enzymatic degradation by nucleases in vivo. Both viral and non-viral delivery vectors have been developed as a means of addressing these limitations, including lipid nanoparticles (LNPs), exosomes, polymers, and inorganic nanoparticles. Among these, LNPs have garnered significant attention due to their superior biocompatibility, high delivery efficiency and customizable design potential, as demonstrated by the clinical success of the FDA-approved siRNA drug Onpattro®. The critical role of nucleic acid drug carriers is discussed in this review. It also outlines the major types of carriers under development and examines the advancements and applications in LNP-based systems for nucleic acid delivery. By conducting a review of recent advancements in LNP design, delivery mechanisms, and clinical applications, this article aims to clarify the ways in which LNPs overcome delivery barriers, compare LNPs with other carriers, and identify key trends that can inform the development of next-generation LNP platforms for nucleic acid therapeutics.

Keywords

Nucleic acid therapeutics / Nucleic acid drugs / Delivery systems / Nucleic acid delivery challenges / Lipid nanoparticle carriers

Cite this article

Download citation ▾
Xuan Lin, Hongguang Xiang, Jiong Wu, Ruixi Liao, Yuhao Li, Bohui Xu, Ying Xu, Yan Shen, Qian Li, Yu Tian. The evolution of lipid nanoparticles: Paving the way for next-generation nucleic acid medicines. Asian Journal of Pharmaceutical Sciences, 2026, 21 (1) : 101121 DOI:10.1016/j.ajps.2026.101121

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev 2021; 178: 113834.

[2]

Chen C, Yang Z, Tang X. Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy. Med Res Rev 2018; 38: 829-69.

[3]

Pardi N, Hogan MJ, Porter FW, Weissman D. MRNA vaccines: a new era in vaccinology. Nat Rev Drug Discov 2018; 17: 261-79.

[4]

Vaughan HJ, Green JJ, Tzeng SY. Cancer-targeting nanoparticles for combinatorial nucleic acid delivery. Adv Mater 2020; 32: e1901081.

[5]

Migliorati JM, Liu S, Liu A, Gogate A, Nair S, Bahal R, et al. Absorption, distribution, metabolism, and excretion of us food and drug administration-approved antisense oligonucleotide drugs. Drug Metab Dispos 2022; 50: 888-97.

[6]

Szabó GT, Mahiny AJ, Vlatkovic I. Covid-19 mRNA vaccines: platforms and current developments. Mol Ther 2022; 30: 1850-68.

[7]

Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al. Advances in covid-19 mRNA vaccine development. Signal Transduct Target Ther 2022; 7: 94.

[8]

Sahin U, Karikó K, Türeci Ö. MRNA-based therapeutics - Developing a new class of drugs. Nat Rev Drug Discov 2014; 13: 759-80.

[9]

Yamada Y. Nucleic acid drugs-current status, issues, and expectations for exosomes. Cancers (Basel) 2021; 13: 5002.

[10]

Jiang Y, Jiang B, Wang Z, Li Y, Cheung JCW, Yin B, et al. Nucleic acid armor: fortifying RNA therapeutics through delivery and targeting innovations for immunotherapy. Int J Mol Sci 2024; 25: 8888.

[11]

Lin M, Qi X. Advances and challenges of stimuli-responsive nucleic acids delivery system in gene therapy. Pharmaceutics 2023; 15: 1450.

[12]

Chan KY, Kinghorn AB, Hollenstein M, Tanner JA. Chemical modifications for a next generation of nucleic acid aptamers. Chembiochem 2022; 23: e202200006.

[13]

Heiss M, Kellner S. Detection of nucleic acid modifications by chemical reagents. RNA Biol 2017; 14: 1166-74.

[14]

Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther 2020; 5: 101.

[15]

Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021; 6: 1078-94.

[16]

Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc Natl Acad Sci USA 2024; 121: e2307800120.

[17]

Yan Y, Liu XY, Lu A, Wang XY, Jiang LX, Wang JC. Non-viral vectors for RNA delivery. J Control Release 2022; 342: 241-79.

[18]

Kim H, Kwak M. Structures and applications of nucleic acid-based micelles for cancer therapy. Int J Mol Sci 2023; 24: 1592.

[19]

Hager S, Fittler FJ, Wagner E, Bros M. Nucleic acid-based approaches for tumor therapy. Cells 2020; 9: 2061.

[20]

Li Y, Huang B, Xue Z, Gao Y, Zhuo Z. Nucleic acid therapy in pediatric cancer. Pharmacol Res 2022; 184: 106441.

[21]

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang C-C, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21.

[22]

Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377(18): 1723-32.

[23]

Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. EMBO Mol Med 2021; 13: e13243.

[24]

Hueso M, Mallén A, Suñé-Pou M, Aran JM, Suñé-Negre JM, Navarro E. ncRNAs in therapeutics: challenges and limitations in nucleic acid-based drug delivery. Int J Mol Sci 2021; 22: 11596.

[25]

Lu ZG, Shen J, Yang J, Wang JW, Zhao RC, Zhang TL, et al. Nucleic acid drug vectors for diagnosis and treatment of brain diseases. Signal Transduct Target Ther 2023; 8: 39.

[26]

Alexander S, Moghadam MG, Rothenbroker M, Y T Chou L. Addressing the in vivo delivery of nucleic-acid nanostructure therapeutics. Adv Drug Deliv Rev 2023; 199: 114898.

[27]

Della Pelle G, Kostevšek N. Nucleic acid delivery with red-blood-cell-based carriers. Int J Mol Sci 2021; 22: 5264.

[28]

Jiang X, Wang N, Liu C, Zhuo Y, Liang L, Gan Y, et al. Oral delivery of nucleic acid therapeutics: challenges, strategies, and opportunities. Drug Discov Today 2023; 28: 103507.

[29]

Yang C, Wu X, Liu J, Ding B. Stimuli-responsive nucleic acid nanostructures for efficient drug delivery. Nanoscale 2022; 14: 17862-70.

[30]

Yan C, Chen J, Wang C, Yuan M, Kang Y, Wu Z, et al. Milk exosomes-mediated miR-31-5p delivery accelerates diabetic wound healing through promoting angiogenesis. Drug Deliv 2022; 29(1): 214-28.

[31]

Lu M, Xing H, Zheng A, Huang Y, Liang XJ. Overcoming pharmaceutical bottlenecks for nucleic acid drug development. Acc Chem Res 2023; 56: 224-36.

[32]

Barbieri I, Kouzarides T. Role of RNA modifications in cancer. Nat Rev Cancer 2020; 20: 303-22.

[33]

Vaidyanathan S, Azizian KT, Haque AKMA, Henderson JM, Hendel A, Shore S, et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without hplc purification. Mol Ther Nucleic Acids 2018; 12: 530-42.

[34]

Yang J, Liu H, Zhang X. Design, preparation and application of nucleic acid delivery carriers. Biotechnol Adv 2014; 32: 804-17.

[35]

Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. J Control Release 2020; 318: 1-15.

[36]

Zhou W, Zhou Y, Chen X, Ning T, Chen H, Guo Q, et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials 2021; 268: 120546.

[37]

Wan T, Zhong J, Pan Q, Zhou T, Ping Y, Liu X. Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci Adv 2022; 8: eabp9435.

[38]

Zhang X, Xu Y, Ma L, Yu K, Niu Y, Xu X, et al. Essential roles of exosome and circRNA_101093 on ferroptosis desensitization in lung adenocarcinoma. Cancer Commun (Lond) 2022; 42: 287-313.

[39]

Lennaárd AJ, Mamand DR, Wiklander RJ, El Andaloussi S, Wiklander OPB. Optimised electroporation for loading of extracellular vesicles with doxorubicin. Pharmaceutics 2021; 14: 38.

[40]

Cui Y, Guo Y, Kong L, Shi J, Liu P, Li R, et al. A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis. Bioact Mater 2022; 10: 207-21.

[41]

Zhu L, Sun HT, Wang S, Huang SL, Zheng Y, Wang CQ, et al. Isolation and characterization of exosomes for cancer research. J Hematol Oncol 2020; 13: 152.

[42]

Kooijmans SAA, Vader P, Schiffelers RM. Tumour-bound RNA-laden exosomes. Nat Biomed Eng 2017; 1: 634-6.

[43]

Xu M, Feng T, Liu B, Qiu F, Xu Y, Zhao Y, et al. Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies. Theranostics 2021; 11: 8926-44.

[44]

Yang Z, Shi J, Xie J, Wang Y, Sun J, Liu T, et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat Biomed Eng 2020; 4: 69-83.

[45]

Shan S, Chen J, Sun Y, Wang Y, Xia B, Tan H, et al. Functionalized macrophage exosomes with panobinostat and ppm1d-siRNA for diffuse intrinsic pontine gliomas therapy. Adv Sci (Weinh) 2022; 9: e2200353.

[46]

Li D, Wang Y, Jin X, Hu D, Xia C, Xu H, et al. Nk cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice. J Neuroinflammation 2020; 17: 126.

[47]

Zhao L, Wang H, Fu J, Wu X, Liang XY, Liu XY, et al. Microfluidic-based exosome isolation and highly sensitive aptamer exosome membrane protein detection for lung cancer diagnosis. Biosens Bioelectron 2022; 214: 114487.

[48]

He C, Zheng S, Luo Y, Wang B. Exosome theranostics: biology and translational medicine. Theranostics 2018; 8: 237-55.

[49]

Li H, Zhang J, Tan M, Yin Y, Song Y, Zhao Y, et al. Exosomes based strategies for cardiovascular diseases: opportunities and challenges. Biomaterials 2024; 308: 122544.

[50]

Ranjan P, Colin K, Dutta RK, Verma SK. Challenges and future scope of exosomes in the treatment of cardiovascular diseases. J Physiol 2023; 601: 4873-93.

[51]

Bai C, Liu J, Zhang X, Li Y, Qin Q, Song H, et al. Research status and challenges of plant-derived exosome-like nanoparticles. Biomed Pharmacother 2024; 174: 116543.

[52]

Kooijmans SAA, Stremersch S, Braeckmans K, de Smedt SC, Hendrix A, Wood MJA, et al. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J Control Release 2013; 172: 229-38.

[53]

Tang TT, Wang B, Lv LL, Dong Z, Liu BC. Extracellular vesicles for renal therapeutics: state of the art and future perspective. J Control Rel 2022; 349: 32-50.

[54]

Liu H, Deng S, Han L, Ren Y, Gu J, He L, et al. Mesenchymal stem cells, exosomes and exosome-mimics as smart drug carriers for targeted cancer therapy. Coll Surf B: Biointerf 2022; 209: 112163.

[55]

Kojima R, Bojar D, Rizzi G, Hamri GC, El-Baba MD, Saxena P, et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for parkinson’s disease treatment. Nat Commun 2018; 9(1): 1305.

[56]

Huang S, Kamihira M. Development of hybrid viral vectors for gene therapy. Biotechnol Adv 2013; 31: 208-23.

[57]

Boeckle S, Wagner E. Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems. AAPS J 2006; 8: E731-42.

[58]

Mogler MA, Kamrud KI. RNA-based viral vectors. Expert Rev Vacc 2015; 14: 283-312.

[59]

Tucci F, Calbi V, Barzaghi F, Migliavacca M, Ferrua F, Bernardo ME, et al. Successful treatment with ledipasvir/sofosbuvir in an infant with severe combined immunodeficiency caused by adenosine deaminase deficiency with HCV allowed gene therapy with strimvelis. Hepatology 2018; 68: 2434-7.

[60]

Monaco L, Faccio L. Patient-driven search for rare disease therapies: the fondazione telethon success story and the strategy leading to strimvelis. EMBO Mol Med 2017; 9: 289-92.

[61]

Rajagopal P, Duraiswamy S, Sethuraman S, Giridhara Rao J, Krishnan UM. Polymer-coated viral vectors: hybrid nanosystems for gene therapy. J Gene Med 2018; 20: e3011.

[62]

Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJE, et al. Viral vectors for malaria vaccine development. Vaccine 2007; 25: 2567-74.

[63]

Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology 2017; 120: 63-80.

[64]

Schwartze JT, Havenga M, Bakker WAM, Bradshaw AC, Nicklin SA. Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. J Mol Med (Berl) 2022; 100: 875-901.

[65]

Del Papa J, Parks RJ. Adenoviral vectors armed with cell fusion-inducing proteins as anti-cancer agents. Viruses 2017; 9: 13.

[66]

Ricobaraza A, Gonzalez-Aparicio M, Mora-Jimenez L, Lumbreras S, Hernandez-Alcoceba R. High-capacity adenoviral vectors: expanding the scope of gene therapy. Int J Mol Sci 2020; 21: 3643.

[67]

Leikas AJ, Ylä-Herttuala S, Hartikainen JEK. Adenoviral gene therapy vectors in clinical use-basic aspects with a special reference to replication-competent adenovirus formation and its impact on clinical safety. Int J Mol Sci 2023; 24: 16519.

[68]

Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med 2022; 386: 1207-20.

[69]

Capasso C, Garofalo M, Hirvinen M, Cerullo V. The evolution of adenoviral vectors through genetic and chemical surface modifications. Viruses 2014; 6: 832-55.

[70]

Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 2019; 18: 358-78.

[71]

Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 2020; 21: 255-72.

[72]

Costa Verdera H, Kuranda K, Mingozzi F. Aav vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 2020; 28: 723-46.

[73]

Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. The Lancet 2017; 390: 849-60.

[74]

Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RMC, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016; 351: 403-7.

[75]

Maeder ML, Stefanidakis M, Wilson CJ, Baral R, Barrera LA, Bounoutas GS, et al. Development of a gene-editing approach to restore vision loss in leber congenital amaurosis type 10. Nat Med 2019; 25: 229-33.

[76]

Ku MW, Charneau P, Majlessi L. Use of lentiviral vectors in vaccination. Expert Rev Vacc 2021; 20: 1571-86.

[77]

Nicolai CJ, Parker MH, Qin J, Tang W, Ulrich-Lewis JT, Gottschalk RJ, et al. In vivo CAR T -cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood 2024; 144: 977-87.

[78]

Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia 2018; 32: 1529-41.

[79]

Arsenijevic Y, Berger A, Udry F, Kostic C. Lentiviral vectors for ocular gene therapy. Pharmaceutics 2022; 14: 1605.

[80]

Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009; 4: 495-505.

[81]

Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, et al. Betibeglogene autotemcel gene therapy for non-β0/ β0 genotype β-thalassemia. New Engl J Med 2022; 386: 415-27.

[82]

Cowan MJ, Yu J, Facchino J, Fraser-Browne C, Sanford U, Kawahara M, et al. Lentiviral gene therapy for artemis-deficient SCID. N Engl J Med 2022; 387: 2344-55.

[83]

Frank AM, Braun AH, Scheib L, Agarwal S, Schneider IC, Fusil F, et al. Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Adv 2020; 4: 5702-15.

[84]

Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther 2020; 28: 709-22.

[85]

Nguyen DN, Roth TL, Li PJ, Chen PA, Apathy R, Mamedov MR, et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat Biotechnol 2020; 38: 44-9.

[86]

Suberi A, Grun MK, Mao T, Israelow B, Reschke M, Grundler J, et al. Polymer nanoparticles deliver mRNA to the lung for mucosal vaccination. Sci Transl Med 2023; 15:eabq0603.

[87]

Jiang AY, Witten J, Raji IO, Eweje F, MacIsaac C, Meng S, et al. Combinatorial development of nebulized mRNA delivery formulations for the lungs. Nat Nanotechnol 2024; 19: 364-75.

[88]

Porello I, Bono N, Candiani G, Cellesi F. Advancing nucleic acid delivery through cationic polymer design: non-cationic building blocks from the toolbox. Polym Chem 2024; 15: 2800-26.

[89]

Kuang G, Lu H, He S, Xiong H, Yu J, Zhang Q, et al. Near-infrared light-triggered polyprodrug/siRNA loaded upconversion nanoparticles for multi-modality imaging and synergistic cancer therapy. Adv Healthc Mater 2021; 10: 2100938.

[90]

Fahira AI, Amalia R, Barliana MI, Gatera VA, Abdulah R. Polyethyleneimine (PEI) as a polymer-based co-delivery system for breast cancer therapy. Breast Cancer 2022; 14: 71-83.

[91]

Zhu S, Xing H, Gordiichuk P, Park J, Mirkin CA. PLGA spherical nucleic acids. Adv Mater 2018; 30: e1707113.

[92]

Swider E, Koshkina O, Tel J, Cruz LJ, de Vries IJM, Srinivas M. Customizing poly(lactic-co-glycolic acid) particles for biomedical applications. Acta Biomater 2018; 73: 38-51.

[93]

Herranz-Blanco B, Shahbazi M-A, Correia AR, Balasubramanian V, Kohout T, Hirvonen J, et al. pH-switch nanoprecipitation of polymeric nanoparticles for multimodal cancer targeting and intracellular triggered delivery of doxorubicin. Adv Healthc Mater 2016; 5: 1904-16.

[94]

Liu X, Liang Y, Peng Y, Meng T, Xu L, Dong P. Sensitivity of the transport of plastic nanoparticles to typical phosphates associated with ionic strength and solution pH. Int J Mol Sci 2022; 23: 9860.

[95]

Mendes BB, Conniot J, Avital A, Yao D, Jiang X, Zhou X, et al. Nanodelivery of nucleic acids. Nat Rev Methods Primers 2022; 2: 1-21.

[96]

Chahal JS, Khan OF, Cooper CL, McPartlan JS, Tsosie JK, Tilley LD, et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and toxoplasma gondii challenges with a single dose. Proc Natl Acad Sci USA 2016; 113: E4133-42.

[97]

Buchman JT, NV Hudson-Smith, Landy KM, Haynes CL. Understanding nanoparticle toxicity mechanisms to inform redesign strategies to reduce environmental impact. Acc Chem Res 2019; 52: 1632-42.

[98]

Beach MA, Nayanathara U, Gao Y, Zhang C, Xiong Y, Wang Y, et al. Polymeric nanoparticles for drug delivery. Chem Rev 2024; 124: 5505-616.

[99]

Kim J, Wilson DR, Zamboni CG, Green JJ. Targeted polymeric nanoparticles for cancer gene therapy. J Drug Target 2015; 23: 627-41.

[100]

Hei MW, Zhan YR, Chen P, Zhao RM, Tian XL, Yu XQ, et al. Lipoic acid-based poly(disulfide)s as versatile biomolecule delivery vectors and the application in tumor immunotherapy. Mol Pharm 2023; 20: 3210-22.

[101]

Eweje F, Walsh ML, Ahmad K, Ibrahim V, Alrefai A, Chen J, et al. Protein-based nanoparticles for therapeutic nucleic acid delivery. Biomaterials 2024; 305: 122464.

[102]

Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 2005; 107: 276-87.

[103]

Zuris JA, Thompson DB, Shu Y, Guilinger JP, Bessen JL, Hu JH, et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat Biotechnol 2015; 33: 73-80.

[104]

Gouveia MG, Wesseler JP, Ramaekers J, Weder C, Scholten PBV, Bruns N. Polymersome-based protein drug delivery - quo vadis? Chem Soc Rev 2023; 52: 728-78.

[105]

Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release 2012; 161: 38-49.

[106]

Serna N, Sánchez-García L, Unzueta U, Díaz R, Vázquez E, Mangues R, et al. Protein-based therapeutic killing for cancer therapies. Trends Biotechnol 2018; 36: 318-35.

[107]

Cossu J, Thoreau F, Boturyn D. Multimeric rgd-based strategies for selective drug delivery to tumor tissues. Pharmaceutics 2023; 15: 525.

[108]

Li Y, Yang H, Zong X, Li X, Yuan P, Yang C, et al. Oncolytic virus-like nanoparticles for tumor-specific gene delivery. Adv Funct Mater 2024; 34: 2314898.

[109]

Ferraro C, Dattilo M, Patitucci F, Prete S, Scopelliti G, Parisi OI, et al. Exploring protein-based carriers in drug delivery: a review. Pharmaceutics 2024; 16: 1172.

[110]

Cheng Z, Li Y, Zhao D, Zhao W, Wu M, Zhang W, et al. Nanocarriers for intracellular co-delivery of proteins and small-molecule drugs for cancer therapy. Front Bioeng Biotechnol 2022; 10: 994655.

[111]

Mustafai A, Zubair M, Hussain A, Ullah A. Recent progress in proteins-based micelles as drug delivery carriers. Polymers (Basel) 2023; 15: 836.

[112]

Luther DC, Huang R, Jeon T, Zhang X, Lee YW, Nagaraj H, et al. Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Adv Drug Deliv Rev 2020; 156: 188-213.

[113]

Li J, Wang S, Shi X, Shen M. Aqueous-phase synthesis of iron oxide nanoparticles and composites for cancer diagnosis and therapy. Adv Colloid Interface Sci 2017; 249: 374-85.

[114]

Alnasraui AHF, Joe IH, Al-Musawi S. Design and synthesize of folate decorated Fe3O4@Au-DEX-CP nano formulation for targeted drug delivery in colorectal cancer therapy: in vitro and in vivo studies. J Drug Deliv Sci Technol 2023; 87: 104798.

[115]

Abdulwahid FS, Haider AJ, Al-Musawi S. Effect of laser parameter on fe3o4 nps formation by pulsed laser ablation in liquid. AIP Conf Proc 2023; 2769: 020039.

[116]

Kumar S, Diwan A, Singh P, Gulati S, Choudhary D, Mongia A, et al. Functionalized gold nanostructures: promising gene delivery vehicles in cancer treatment. RSC Adv 2019; 9(41): 23894-907.

[117]

Tang C, He Z, Liu H, Xu Y, Huang H, Yang G, et al. Application of magnetic nanoparticles in nucleic acid detection. J Nanobiotechnology 2020; 18: 62.

[118]

Arami H, Khandhar A, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev 2015; 44: 8576-607.

[119]

Rajchakit U, Sarojini V. Recent developments in antimicrobial-peptide-conjugated gold nanoparticles. Bioconjug Chem 2017; 28: 2673-86.

[120]

Turkmen Koc SN, Rezaei Benam S, Aral IP, Shahbazi R, Ulubayram K. Gold nanoparticles-mediated photothermal and photodynamic therapies for cancer. Int J Pharm 2024; 655: 124057.

[121]

Ding Y, Jiang Z, Saha K, Kim CS, Kim ST, Landis RF, et al. Gold nanoparticles for nucleic acid delivery. Mol Ther 2014; 22: 1075-83.

[122]

Ferreira D, Fontinha D, Martins C, Pires D, Fernandes AR, Baptista PV. Gold nanoparticles for vectorization of nucleic acids for cancer therapeutics. Molecules 2020; 25: 3489.

[123]

Hosseini SA, Kardani A, Yaghoobi H. A comprehensive review of cancer therapies mediated by conjugated gold nanoparticles with nucleic acid. Int J Biol Macromol 2023; 253: 127184.

[124]

Xue C, Hu S, Gao Z-H, Wang L, Luo M-X, Yu X, et al. Programmably tiling rigidified DNA brick on gold nanoparticle as multi-functional shell for cancer-targeted delivery of siRNAs. Nat Commun 2021; 12: 2928.

[125]

Zhang Y, Yu Y, Yang Y, Wang Y, Yu C. Engineered silica nanoparticles for nucleic acid delivery. Small Meth 2024; 8: e2300812.

[126]

Juneja R, Vadarevu H, Halman J, Tarannum M, Rackley L, Dobbs J, et al. Combination of nucleic acid and mesoporous silica nanoparticles: optimization and therapeutic performance in vitro. ACS Appl Mater Interfaces 2020; 12: 38873-86.

[127]

Cha W, Fan R, Miao Y, Zhou Y, Qin C, Shan X, et al. Mesoporous silica nanoparticles as carriers for intracellular delivery of nucleic acids and subsequent therapeutic applications. Molecules 2017; 22: 782.

[128]

Fang G, Zhang A, Zhu L, Wang Q, Sun F, Tang B. Nanocarriers containing platinum compounds for combination chemotherapy. Front Pharmacol 2022; 13: 1050928.

[129]

Cruz-Acuña M, Halman JR, Afonin KA, Dobson J, Rinaldi C. Magnetic nanoparticles loaded with functional RNA nanoparticles. Nanoscale 2018; 10: 17761-70.

[130]

De Matteis V. Exposure to inorganic nanoparticles: routes of entry, immune response, biodistribution and in vitro / in vivo toxicity evaluation. Toxics 2017; 5: 29.

[131]

Park S, Ku J, Lee S-M, Hwang H, Lee N, Kim H, et al. Potential toxicity of inorganic ions in particulate matter: ion permeation in lung and disruption of cell metabolism. Sci Total Environ 2022; 824: 153818.

[132]

Mohammadpour R, Dobrovolskaia MA, Cheney DL, Greish KF, Ghandehari H. Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. Adv Drug Deliv Rev 2019; 144: 112-32.

[133]

Zhu J, Batra H, Ananthaswamy N, Mahalingam M, Tao P, Wu X, et al. Design of bacteriophage t4-based artificial viral vectors for human genome remodeling. Nat Commun 2023; 14: 2928.

[134]

Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat Rev Drug Discov 2024; 23: 709-22.

[135]

Tang B, Qian Y, Fang G. Development of lipid-polymer hybrid nanoparticles for improving oral absorption of enoxaparin. Pharmaceutics 2020; 12: 607.

[136]

Kiaie SH, Majidi Zolbanin N, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F, et al. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol 2022; 20: 276.

[137]

Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res 2022; 55: 2-12.

[138]

LoPresti ST, Arral ML, Chaudhary N, Whitehead KA. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J Control Release 2022; 345: 819-31.

[139]

Maeki M, Uno S, Niwa A, Okada Y, Tokeshi M. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. J Control Release 2022; 344: 80-96.

[140]

Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol 2023; 20: 739-54.

[141]

Zong Y, Lin Y, Wei T, Cheng Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv Mater 2023; 35: e2303261.

[142]

Verbeke R, Hogan MJ, Loré K, Pardi N. Innate immune mechanisms of mRNA vaccines. Immunity 2022; 55: 1993-2005.

[143]

Patel S, Ryals RC, Weller KK, Pennesi ME, Sahay G. Lipid nanoparticles for delivery of messenger RNA to the back of the eye. J Control Release 2019; 303: 91-100.

[144]

Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010; 28: 172-6.

[145]

Lam K, Leung A, Martin A, Wood M, Schreiner P, Palmer L, et al. Unsaturated, trialkyl ionizable lipids are versatile lipid-nanoparticle components for therapeutic and vaccine applications. Adv Mater 2023; 35: e2209624.

[146]

Isaac I, Shaikh A, Bhatia M, Liu Q, Park S, Bhattacharya C. Tetrahydropyrimidine ionizable lipids for efficient mRNA delivery. ACS Nano 2024; 18: 29045-58.

[147]

Jörgensen AM, Wibel R, Bernkop-Schnürch A. Biodegradable cationic and ionizable cationic lipids: a roadmap for safer pharmaceutical excipients. Small 2023; 19: e2206968.

[148]

Xu Y, Golubovic A, Xu S, Pan A, Li B. Rational design and combinatorial chemistry of ionizable lipids for RNA delivery. J Mater Chem B 2023; 11: 6527-39.

[149]

Zhang X, Su K, Wu S, Lin L, He S, Yan X, et al. One-component cationic lipids for systemic mRNA delivery to splenic T cells. Angew Chem Int Ed Engl 2024; 63:e202405444.

[150]

Chen K, Fan N, Huang H, Jiang X, Qin S, Xiao W, et al. MRNA vaccines against SARS-CoV-2 variants delivered by lipid nanoparticles based on novel ionizable lipids. Adv Funct Mater 2022; 32: 2204692.

[151]

Sharma P, Breier D, Peer D. Immunogenic amines on lipid nanoparticles. Nat Biomed Eng 2024; 8: 1332-3.

[152]

Wang Y, Si X, Feng Y, Feng D, Xu X, Zhang Y. Ionizable lipids with triazole moiety from click reaction for LNP-based mRNA delivery. Molecules 2023; 28: 4046.

[153]

He T, Wen J, Wang W, Hu Z, Ling C, Zhao Z, et al. Peptide-driven proton sponge nano-assembly for imaging and triggering lysosome-regulated immunogenic cancer cell death. Adv Mater 2024; 36: e2307679.

[154]

Li B, Raji IO, Gordon AGR, Sun L, Raimondo TM, Oladimeji FA, et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat Mater 2024; 23: 1002-8.

[155]

Riley RS, Kashyap MV, Billingsley MM, White B, Alameh MG, Bose SK, et al. Ionizable lipid nanoparticles for in utero mRNA delivery. Sci Adv 2021; 7: eaba1028.

[156]

Xu S, Xu Y, Solek NC, Chen J, Gong F, Varley AJ, et al. Tumor-tailored ionizable lipid nanoparticles facilitate IL-12 circular RNA delivery for enhanced lung cancer immunotherapy. Adv Mater 2024; 36: e2400307.

[157]

Patel SK, Billingsley MM, Mukalel AJ, Thatte AS, Hamilton AG, Gong N, et al. Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery. Theranostics 2024; 14: 1-16.

[158]

Dabora SL, Roberts P, Nieto A, Perez R, Jozwiak S, Franz D, et al. Association between a high-expressing interferon-gamma allele and a lower frequency of kidney angiomyolipomas in TSC2 patients. Am J Hum Genet 2002; 71: 750-8.

[159]

Wang C, Zhang Y, Dong Y. Lipid nanoparticle-mRNA formulations for therapeutic applications. Acc Chem Res 2021; 54: 4283-93.

[160]

Kulkarni JA, Darjuan MM, Mercer JE, Chen S, van der Meel R, Thewalt JL, et al. On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA. ACS Nano 2018; 12: 4787-95.

[161]

El Moukhtari SH, Garbayo E, Amundarain A, Pascual-Gil S, Carrasco-León A, Prosper F, et al. Lipid nanoparticles for siRNA delivery in cancer treatment. J Control Release 2023; 361: 130-46.

[162]

Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 2015; 217: 345-51.

[163]

Gomi M, Sakurai Y, Sato M, Tanaka H, Miyatake Y, Fujiwara K, et al. Delivering mRNA to secondary lymphoid tissues by phosphatidylserine-loaded lipid nanoparticles. Adv Healthc Mater 2023; 12: e2202528.

[164]

Liu S, Cheng Q, Wei T, Yu X, Johnson LT, Farbiak L, et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and crispr-cas gene editing. Nat Mater 2021; 20: 701-10.

[165]

Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol 2020; 15: 313-20.

[166]

Sebastiani F, Yanez Arteta M, Lerche M, Porcar L, Lang C, Bragg RA, et al. Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles. ACS Nano 2021; 15: 6709-22.

[167]

Patel SK, Billingsley MM, Frazee C, Han X, Swingle KL, Qin J, et al. Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells. J Control Release 2022; 347: 521-32.

[168]

Zimmermann CM, Baldassi D, Chan K, Adams NBP, Neumann A, Porras-Gonzalez DL, et al. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery. J Control Release 2022; 351: 137-50.

[169]

Radmand A, Kim H, Beyersdorf J, Dobrowolski CN, Zenhausern R, Paunovska K, et al. Cationic cholesterol-dependent LNP delivery to lung stem cells, the liver, and heart. Proc Natl Acad Sci USA 2024; 121: e2307801120.

[170]

Patel S, Ashwanikumar N, Robinson E, Xia Y, Mihai C, Griffith JP, et al. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat Commun 2020; 11: 983.

[171]

Jung O, Jung HY, Thuy LT, Choi M, Kim S, Jeon HG, et al. Modulating lipid nanoparticles with histidinamide-conjugated cholesterol for improved intracellular delivery of mRNA. Adv Healthc Mater 2024; 13: e2303857.

[172]

Sharma B, Peetla C, Adjei IM, Labhasetwar V. Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy. Cancer Lett 2013; 334: 228-36.

[173]

Gautam M, Jozic A, Su GL, Herrera-Barrera M, Curtis A, Arrizabalaga S, et al. Lipid nanoparticles with peg-variant surface modifications mediate genome editing in the mouse retina. Nat Commun 2023; 14(1): 6468.

[174]

Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZC, Rotolo L, Echeverri ES, et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng 2021; 5: 1059-68.

[175]

Xu Y, Ma S, Cui H, Chen J, Xu S, Gong F, et al. Agile platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat Commun 2024; 15: 6305.

[176]

Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc 2023; 18: 265-91.

[177]

Huang X, Ma Y, Ma G, Xia Y. Unlocking the therapeutic applicability of LNP-mRNA: chemistry, formulation, and clinical strategies. Research (Wash D C) 2024; 7: 0370.

[178]

Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-based nanoparticles for drug/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Mater Au 2023; 3: 600-19.

[179]

Roces CB, Lou G, Jain N, Abraham S, Thomas A, Halbert GW, et al. Manufacturing considerations for the development of lipid nanoparticles using microfluidics. Pharmaceutics 2020; 12: 1095.

[180]

Shirane D, Tanaka H, Sakurai Y, Taneichi S, Nakai Y, Tange K, et al. Development of an alcohol dilution-lyophilization method for the preparation of mRNA-LNPs with improved storage stability. Pharmaceutics 2023; 15: 1819.

[181]

Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, Amankwa L, et al. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release 2010; 144: 332-40.

[182]

Guimaraes PPG, Zhang R, Spektor R, Tan M, Chung A, Billingsley MM, et al. Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening. J Control Release 2019; 316: 404-17.

[183]

Huang Y, Liu C, Feng Q, Sun J. Microfluidic synthesis of nanomaterials for biomedical applications. Nanoscale Horiz 2023; 8: 1610-27.

[184]

Liu S, Wen Y, Shan X, Ma X, Yang C, Cheng X, et al. Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination. Nat Commun 2024; 15: 9471.

[185]

Islam F, Das S, Ashaduzzaman M, Sillman B, Yeapuri P, Nayan MU, et al. Development of an extended action fostemsavir lipid nanoparticle. Commun Biol 2024; 7: 1-17.

[186]

Ferraresso F, Strilchuk AW, Juang LJ, Poole LG, Luyendyk JP, Kastrup CJ. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells. Mol Pharm 2022; 19: 2175-82.

[187]

Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 2013; 31: 638-46.

[188]

Maugeri M, Nawaz M, Papadimitriou A, Angerfors A, Camponeschi A, Na M, et al. Linkage between endosomal escape of LNP-mRNA and loading into evs for transport to other cells. Nat Commun 2019; 10: 4333.

[189]

Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol 2013; 31: 653-8.

[190]

Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 2024; 20: e2304378.

[191]

Tanaka H, Akita H, Ishiba R, Tange K, Arai M, Kubo K, et al. Neutral biodegradable lipid-envelope-type nanoparticle using vitamin A-scaffold for nuclear targeting of plasmid DNA. Biomaterials 2014; 35: 1755-61.

[192]

Young RE, Nelson KM, Hofbauer SI, Vijayakumar T, Alameh M-G, Weissman D, et al. Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach. Bioact Mater 2024; 34: 125-37.

[193]

Homma K, Miura Y, Kobayashi M, Chintrakulchai W, Toyoda M, Ogi K, et al. Fine tuning of the net charge alternation of polyzwitterion surfaced lipid nanoparticles to enhance cellular uptake and membrane fusion potential. Sci Technol Adv Mater 2024; 25: 2338785.

[194]

Hołubowicz R, Du SW, Felgner J, Smidak R, Choi EH, Palczewska G, et al. Safer and efficient base editing and prime editing via ribonucleoproteins delivered through optimized lipid-nanoparticle formulations. Nat Biomed Eng 2025; 9(1): 57-78.

[195]

Evers MJW, Du W, Yang Q, Kooijmans SAA, Vink A, van Steenbergen M, et al. Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles. J Control Release 2022; 343: 207-16.

[196]

Hamilton AG, Swingle KL, Thatte AS, Mukalel AJ, Safford HC, Billingsley MM, et al. High-throughput in vivo screening identifies differential influences on mRNA lipid nanoparticle immune cell delivery by administration route. ACS Nano 2024; 18: 16151-65.

[197]

Lokugamage MP, Gan Z, Zurla C, Levin J, Islam FZ, Kalathoor S, et al. Mild innate immune activation overrides efficient nanoparticle-mediated RNA delivery. Adv Mater 2020; 32: e1904905.

[198]

Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science 2022; 375: 91-6.

[199]

Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA vaccines protect against zika virus infection. Cell 2017; 168: 1114-25 e10.

[200]

Zhang R, Shao S, Piao Y, Xiang J, Wei X, Zhang Z, et al. Esterase-labile quaternium lipidoid enabling improved mRNA-LNP stability and spleen-selective mRNA transfection. Adv Mater 2023; 35: e2303614.

[201]

Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008; 16: 1833-40.

[202]

Parhiz H, Atochina-Vasserman EN, Weissman D. MRNA-based therapeutics: looking beyond COVID-19 vaccines. Lancet 2024; 403: 1192-204.

[203]

Kim M, Jeong M, Hur S, Cho Y, Park J, Jung H, et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci Adv 2021; 7: eabf4398.

[204]

Liu S, Wen Y, Shan X, Ma X, Yang C, Cheng X, et al. Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination. Nat Commun 2024; 15: 9471.

[205]

Kim Y, Choi J, Kim EH, Park W, Jang H, Jang Y, et al. Design PD-L1-targeted lipid nanoparticles to turn on PTEN for efficient cancer therapy. Adv Sci (Weinh) 2024; 11: e2309917.

[206]

Geisler HC, Ghalsasi AA, Safford HC, Swingle KL, Thatte AS, Mukalel AJ, et al. EGFR -targeted ionizable lipid nanoparticles enhance in vivo mRNA delivery to the placenta. J Control Release 2024; 371: 455-69.

[207]

Parhiz H, Shuvaev VV, Pardi N, Khoshnejad M, Kiseleva RY, Brenner JS, et al. PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. J Control Release 2018; 291: 106-15.

[208]

Aliakbarinodehi N, Gallud A, Mapar M, Wesén E, Heydari S, Jing Y, et al. Interaction kinetics of individual mRNA-containing lipid nanoparticles with an endosomal membrane mimic: dependence on pH, protein corona formation, and lipoprotein depletion. ACS Nano 2022; 16: 20163-73.

[209]

Maestro S, Weber ND, Zabaleta N, Aldabe R, Gonzalez-Aseguinolaza G. Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep 2021; 3: 100300.

[210]

Song D, Zhao Y, Wang Z, Xu Q. Tuning lipid nanoparticles for RNA delivery to extrahepatic organs. Adv Mater 2024; 36: e2401445.

[211]

Mahalingam G, Rachamalla HK, Arjunan P, Karuppusamy KV, Periyasami Y, Mohan A, et al. Smart-lipid nanoparticles enabled mRNA vaccine elicits cross-reactive humoral responses against the omicron sub-variants. Mol Ther 2024; 32: 1284-97.

[212]

Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers (Basel) 2019; 11: 640.

[213]

Bian X, Yang L, Jiang D, Grippin AJ, Ma Y, Wu S, et al. Regulation of cerebral blood flow boosts precise brain targeting of vinpocetine-derived ionizable-lipidoid nanoparticles. Nat Commun 2024; 15: 3987.

[214]

Renzi S, Digiacomo L, Pozzi D, Quagliarini E, Vulpis E, Giuli MV, et al. Structuring lipid nanoparticles, DNA, and protein corona into stealth bionanoarchitectures for in vivo gene delivery. Nat Commun 2024; 15: 9119.

[215]

Pattipeiluhu R, Arias-Alpizar G, Basha G, Chan KYT, Bussmann J, Sharp TH, et al. Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system. Adv Mater 2022; 34: e2201095.

[216]

Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc Chem Res 2019; 52: 2435-44.

[217]

Lokugamage MP, Gan Z, Zurla C, Levin J, Islam FZ, Kalathoor S, et al. Mild innate immune activation overrides efficient nanoparticle-mediated RNA delivery. Adv Mater 2020; 32: e1904905.

[218]

Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol Ther 2024; 32: 284-312.

[219]

Breda L, Papp TE, Triebwasser MP, Yadegari A, Fedorky MT, Tanaka N, et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 2023; 381: 436-43.

[220]

Wang L, Zhu L, Liang C, Huang X, Liu Z, Huo J, et al. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis. J Hepatol 2023; 79: 1185-200.

[221]

Zhang C, Teng Y, Bai X, Tang M, Stewart W, Chen JJ, et al. Prevent and reverse metabolic dysfunction-associated steatohepatitis and hepatic fibrosis via mRNA-mediated liver-specific antibody therapy. ACS Nano 2024; 18(50): 34375-90.

[222]

Chen YC, Lee YL, Lee CA, Lin TY, Hwu EET, Cheng PC. Development of a lipid-encapsulated tgf βri-siRNA drug for liver fibrosis induced by Schistosoma mansoni. PLoS Negl Trop Dis 2024; 18: e0012502.

[223]

Rivero Berti I, Gambaro RC, Limeres MJ, Huck-Iriart C, Svensson M, Fraude-El Ghazi S, et al. Encapsulation of dexamethasone into mRNA-lipid nanoparticles is a promising approach for the development of liver-targeted anti-inflammatory therapies. Int J Mol Sci 2024; 25: 11254.

[224]

Maurer MS, Kale P, Grogan M, Gustafsson F, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med 2023; 389: 1553-65.

[225]

Cheng Z, Wei W, Chen Y, Xu A, Wang Y, Li B. Construction of nanoparticles from blueberry anthocyanins-lecithin/gum arabic improves lipid droplet accumulation and gut microbiota disturbance in HFD-induced obese mice. Int J Biol Macromol 2024; 264: 130595.

[226]

Al Fayez N, Rouhollahi E, Ong CY, Wu J, Nguyen A, Böttger R, et al. Hepatocyte-targeted delivery of imiquimod reduces hepatitis B virus surface antigen. J Control Release 2022; 350: 630-41.

[227]

Wu S, Su K, Yan X, Shi L, Lin L, Ren E, et al. Paracyclophane-based ionizable lipids for efficient mRNA delivery in vivo. J Control Release 2024; 376: 395-401.

[228]

Ferrini M, Carvalho S, Cho YH, Postma B, Miranda Marques L, Pinkerton K, et al. Prenatal tobacco smoke exposure predisposes offspring mice to exacerbated allergic airway inflammation associated with altered innate effector function. Part Fibre Toxicol 2017; 14: 30.

[229]

Sadiq MW, Holz O, Ellinghusen BD, Faulenbach C, Müller M, Badorrek P, et al. Lung pharmacokinetics of inhaled and systemic drugs: a clinical evaluation. Br J Pharmacol 2021; 178: 4440-51.

[230]

Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, et al. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol 2021; 75: 1420-33.

[231]

Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C, et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2022; 119: e2116271119.

[232]

Zeng G, He Z, Yang H, Gao Z, Ge X, Liu L, et al. Cationic lipid pairs enhance liver-to-lung tropism of lipid nanoparticles for in vivo mRNA delivery. ACS Appl Mater Interfaces 2024; 16: 25698-709.

[233]

Zhao G, Xue L, Weiner AI, Gong N, Adams-Tzivelekidis S, Wong J, et al. TGF- βR2 signaling coordinates pulmonary vascular repair after viral injury in mice and human tissue. Sci Transl Med 2024; 16: eadg6229.

[234]

Kassab G, Doran K, Mo Y, Zheng G. Inhalable gene therapy and the lung surfactant problem. Nano Lett 2023; 23: 10099-102.

[235]

Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14: 535-46.

[236]

Cina C, Majeti B, O’Brien Z, Wang L, Clamme JP, Adami R, et al. A novel lipid nanoparticle nbf-006 encapsulating glutathione s-transferase p siRNA for the treatment of KRAS-driven non-small cell lung cancer. Mol. Cancer Ther. 2025; 24(1): 7-17.

[237]

Zimmermann CM, Baldassi D, Chan K, Adams NBP, Neumann A, Porras-Gonzalez DL, et al. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery. J Control Release 2022; 351: 137-50.

[238]

Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev 2019; 99: 21-78.

[239]

Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23: 858-83.

[240]

Ganbold T, Bao Q, Xiao H, Zurgaanjin D, Liu C, Han S, et al. Peptidomimetic lipid-nanoparticle-mediated knockdown of tlr4 in CNS protects against cerebral ischemia/reperfusion injury in mice. Nanomaterials (Basel) 2022; 12: 2072.

[241]

Khare P, Edgecomb SX, Hamadani CM, Conway JF, Tanner EEL, S Manickam D. Ionic liquid-coated lipid nanoparticles increase siRNA uptake into CNS targets. Nanoscale Adv 2024; 6: 1853-73.

[242]

Gao M, Li Y, Ho W, Chen C, Chen Q, Li F, et al. Targeted mRNA nanoparticles ameliorate blood-brain barrier disruption postischemic stroke by modulating microglia polarization. ACS Nano 2024; 18: 3260-75.

[243]

Spitz F, Gonzalez F, Duboule D. A global control region defines a chromosomal regulatory landscape containing the HoxD cluster. Cell 2003; 113: 405-17.

[244]

Tang L, Zhang R, Wang Y, Liu M, Hu D, Wang Y, et al. A blood-brain barrier- and blood-brain tumor barrier-penetrating siRNA delivery system targeting gliomas for brain tumor immunotherapy. J Control Release 2024; 369: 642-57.

[245]

Pardridge WM. Brain gene therapy with Trojan horse lipid nanoparticles. Trends Mol Med 2023; 29: 343-53.

[246]

Ogawa K, Kato N, Yoshida M, Hiu T, Matsuo T, Mizukami S, et al. Focused ultrasound/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain. J Control Release 2022; 348: 34-41.

[247]

Ralvenius WT, Andresen JL, Huston MM, Penney J, Bonner JM, Fenton OS, et al. Nanoparticle-mediated delivery of anti-pu.1 siRNA via localized intracisternal administration reduces neuroinflammation. Adv Mater 2024; 36: e2309225.

[248]

Olson KE, Namminga KL, Lu Y, Thurston MJ, Schwab AD, de Picciotto S, et al. Granulocyte-macrophage colony-stimulating factor mRNA and neuroprotective immunity in Parkinson’s disease. Biomaterials 2021; 272: 120786.

[249]

Wu X, Yuan R, Xu Y, Wang K, Yuan H, Meng T, et al. Functionalized lipid nanoparticles modulate the blood-brain barrier and eliminate α-synuclein to repair dopamine neurons. Asian J Pharm Sci 2024; 19: 100904.

[250]

Wu Y, Wang J, Deng Y, Angelov B, Fujino T, Hossain MS, et al. Lipid and transcriptional regulation in a parkinson’s disease mouse model by intranasal vesicular and hexosomal plasmalogen-based nanomedicines. Adv Healthc Mater 2024; 13: e2304588.

[251]

Billingsley MM, Gong N, Mukalel AJ, Thatte AS, El-Mayta R, Patel SK, et al. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism. Small 2024; 20: e2304378.

[252]

Soroudi S, Jaafari MR, Arabi L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: advances in genome editing and CAR T cell therapy. J Control Release 2024; 372: 113-40.

[253]

OA Marcos-Contreras, Greineder CF, Kiseleva RY, Parhiz H, Walsh LR, Zuluaga-Ramirez V, et al. Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier. Proc Natl Acad Sci USA 2020; 117: 3405-14.

[254]

Parhiz H, Shuvaev VV, Li Q, Papp TE, Akyianu AA, Shi R, et al. Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system. Mol Ther Nucleic Acids 2024; 35: 102175.

[255]

Nawaz M, Heydarkhan-Hagvall S, Tangruksa B, González-King Garibotti H, Jing Y, Maugeri M, et al. Lipid nanoparticles deliver the therapeutic VEGFA mRNA in vitro and in vivo and transform extracellular vesicles for their functional extensions. Adv Sci (Weinh) 2023; 10: e2206187.

[256]

Back PI, Yu M, Modaresahmadi S, Hajimirzaei S, Zhang Q, Islam MR, et al. Immune implications of cholesterol-containing lipid nanoparticles. ACS Nano 2024; 18: 28480-501.

[257]

Tadin-Strapps M, Peterson LB, Cumiskey A-M, Rosa RL, Mendoza VH, Castro-Perez J, et al. SiRNA-induced liver apob knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res 2011; 52: 1084-97.

[258]

Niu X, Zhang J, Zhang J, Bai L, Hu S, Zhang Z, et al. Lipid nanoparticle-mediated Oip5-as1 delivery preserves mitochondrial function in myocardial ischemia/reperfusion injury by inhibiting the p53 pathway. ACS Appl Mater Interfaces 2024; 16: 61565-82.

[259]

Li H, Peng K, Yang K, Ma W, Qi S, Yu X, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics 2022; 12: 6422-36.

[260]

Liu JQ, Zhang C, Zhang X, Yan J, Zeng C, Talebian F, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Control Release 2022; 345: 306-13.

[261]

Nguyen H-M, Alexander KE, Collinge M, Hickey JC, Lanz TA, Li J, et al. mRNA-LNPs induce immune activation and cytokine release in human whole blood assays across diverse health conditions. Mol Ther 2025; 33(6): 2872-85.

[262]

Kon E, Ad-El N, Hazan-Halevy I, Stotsky-Oterin L, Peer D. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects. Nat Rev Clin Oncol 2023; 20: 739-54.

[263]

Yang T, Poenisch M, Khanal R, Hu Q, Dai Z, Li R, et al. Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model. J Hepatol 2021; 75: 1420-33.

[264]

Michels A, Ho N, Buchholz CJ. Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms. Mol Ther 2022; 30: 2401-15.

[265]

Hamouda AEI, Filtjens J, Brabants E, Kancheva D, Debraekeleer A, Brughmans J, et al. Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity. Nat Commun 2024; 15: 10635.

[266]

Fei Y, Yu X, Liu P, Ren H, Wei T, Cheng Q. Simplified lipid nanoparticles for tissue- and cell-targeted mRNA delivery facilitate precision tumor therapy in a lung metastasis mouse model. Adv Mater 2024; 36: e2409812.

[267]

Kubara K, Yamazaki K, Miyazaki T, Kondo K, Kurotaki D, Tamura T, et al. Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines. Mol Ther 2024; 32: 704-21.

[268]

Chen J, Chen J, Xu Q. Current developments and challenges of mRNA vaccines. Annu Rev Biomed Eng 2022; 24: 85-109.

[269]

Ramos da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, et al. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med 2023; 15: eabn3464.

[270]

Nakamura T, Sato T, Endo R, Sasaki S, Takahashi N, Sato Y, et al. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J Immunother Cancer 2021; 9: e002852.

[271]

Shi G, Xu Y, Qiu H, Cao F, Xiao ZX, Zhang C, et al. Personalized membrane protein vaccine based on a lipid nanoparticle delivery system prevents postoperative recurrence in colorectal cancer models. Acta Biomater 2025; 192: 315-27.

[272]

Igyártó BZ, Qin Z. The mRNA-LNP vaccines: the good, the bad and the ugly? Front Immunol 2024; 15: 1336906.

[273]

Vasileva O, Zaborova O, Shmykov B, Ivanov R, Reshetnikov V. Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics. Front Pharmacol 2024; 15: 1466337.

[274]

Yang L, Gong L, Wang P, Zhao X, Zhao F, Zhang Z, et al. Recent advances in lipid nanoparticles for delivery of mRNA. Pharmaceutics 2022; 14: 2682.

[275]

Lee K, Jang B, Lee YR, Suh EY, Yoo JS, Lee MJ, et al. The cutting-edge technologies of siRNA delivery and their application in clinical trials. Arch Pharm Res 2018; 41: 867-874.

[276]

Bader J, Brigger F, Leroux J-C. Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Adv Drug Deliv Rev 2024; 215: 115461.

[277]

Qiu M, Li Y, Bloomer H, Xu Q. Developing biodegradable lipid nanoparticles for intracellular mRNA delivery and genome editing. Acc Chem Res 2021; 54: 4001-11.

[278]

Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther 2018; 28: 146-57.

[279]

Zai W, Yang M, Jiang K, Guan J, Wang H, Hu K, et al. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection. Signal Transduct Target Ther 2024; 9: 150.

[280]

Helms AS, Thompson AD, Day SM. Translation of new and emerging therapies for genetic cardiomyopathies. JACC Basic Transl Sci 2022; 7: 70-83.

[281]

Vijayan A, Vogels R, Groppo R, Jin Y, Khan S, Van Kampen M, et al. A self-amplifying RNA RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates. Nat Commun 2024; 15: 9884.

[282]

Schwartz MR, Debski AC, Price RJ. Ultrasound-targeted nucleic acid delivery for solid tumor therapy. J Control Release 2021; 339: 531-46.

[283]

Traber GM, Yu AM. RNAi-based therapeutics and novel RNA bioengineering technologies. J Pharmacol Exp Ther 2023; 384: 133-54.

[284]

Simonsen JB. Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies - challenges and opportunities. J Control Release 2024; 370: 763-72.

[285]

Ramadan E, Ahmed A, Naguib YW. Advances in mRNA LNP -based cancer vaccines: mechanisms, formulation aspects, challenges, and future directions. J Pers Med 2024; 14: 1092.

[286]

Yamazaki K, Kubara K, Ishii S, Kondo K, Suzuki Y, Miyazaki T, et al. Lipid nanoparticle-targeted mRNA formulation as a treatment for ornithine-transcarbamylase deficiency model mice. Mol Ther Nucleic Acids 2023; 33: 210-26.

[287]

Teng F, Fu D, Shi CC, Xiong A, Yang MX, Su C, et al. Nano-energy interference: a novel strategy for blunting tumor adaptation and metastasis. Mater Today Bio 2024; 25: 100984.

[288]

Andresen JL, Fenton OS. Nucleic acid delivery and nanoparticle design for COVID vaccines. MRS Bull 2021; 46: 832-9.

PDF (6591KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉